Expression analysis of miR-21, miR-205, and miR-342 in breast cancer in Iran

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 873-877

  Savad, Shahram ^a   Mehdipour, Parvin ^a   Miryounesi, Mohammad ^a   Shirkoohi, Reza ^b   Fereidooni, Forouzandeh ^c   Mansouri, Fatemeh ^a   Modarressi, Mohammad Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Cancer Research Center   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

breast cancer; MiR 205; MiR 21; MiR 342; P.C.R.; P53; sybr green I real time RT

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; MIRN205 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRN342 MICRORNA, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; FIBROADENOMA; GENETICS; HUMAN; IRAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; FIBROADENOMA; HUMANS; IRAN; LYMPHATIC METASTASIS; MICRORNAS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871708584     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.873     Document Type: Article

References (29)

1. Adachi R, Horiuchi S, Sakurazawa Y, et al (2011). ErbB2 downregulates microRNA-205 in breast cancer. Biochem Biophys Res Commun, 411, 804-8.
2. Ambros V (2003). MicroRNA pathways in flies and worms: Growth,death, fat, stress, and timing. Cell, 113, 673-6.
3. Arteaga C, (2003) Trastuzumab, an appropriate first-line singleagent therapy for HER2/NEU-overexpressing metastatic breast cancer. Breast. Cancer Res, 5, 96-100.
4. Blenkiron C, Goldstein LD, Thorne NP, et al (2007). Micro-RNA expression profiling of human breast cancer identifies new markers of tumor subtype, Genome Biol, 8, 214.
5. Chan JA, Krichevsky AM, Kosik KS (2005). MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells. Cancer Res, 65, 6029-33.
6. Cotran R.S, Kumar V, Robbins SL (1989). Female breast, In: R.S. Cotran, V. Kumar and S.L. Robbins. Robbins pathologic basis of disease. 4th edition. WB Saunders, Philadelphia, pp. 1183-204.
7. Gasco M, Shami S, Crook T, et al (2002). The p53 pathway in breast cancer. Breast Cancer Res, 4, 70-6.
8. Ghaffari SR, Sabokbar T, Dastan J, et al (2011). Her2 Amplification Status in Iranian Breast Cancer Patients:Comparison of Immunohistochemistry (IHC) and Fluorescencein situ Hybridisation (FISH). APJCP, 12, 1031-4.
9. Huang GL, Zhang XH, Guo GL, et al (2009). Clinical significance of miR-21 expression in breast cancer:SYBRGreen I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep, 21, 673-9.
10. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.
11. Jacob S, Praz F (2002). DNA mismatch repair defects: role in colorectal carcinogenesis. Biochimi, 84, 27-47.
12. Lewis BP, Burge CB, Bartel DP, et al (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human\genes are microRNA targets. Cell, 120, 15-20.
13. Li D, Marchenko ND, Schulz R, et al (2011). Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res, 9, 577-88.
14. Lowery AJ, Miller N, Devaney A, et al (2009). MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res, 11, 27-42.
15. Mattie MD, Benz CC, Bowers J, et al (2006). Optimized highthroughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer, 5, 24-9.
16. McCaskill-Stevens W, Abrams JS (2011). Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes? J Natl Cancer Inst, 103, 1072-83.
17. Noguchi S, Motomura K, Inaji H (1993). Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res, 56, 4071-4.
18. Obernosterer G, Leuschner PJ, Alenius M, et al (2006). Posttranscriptional regulation of microRNA expression. RNA, 12, 1161-7.
19. Papagiannakopoulos T, Shapiro A, Kosik KS (2008). Suppressive Pathways in Glioblastoma Cells, Cancer Res, 68 ,8164-72.
20. Pfaffl MW, Horgan GW, Dempfle L, (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res, 30, 36.
21. Qi L, Bart J, Tan LP, et al (2009). Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma, BMC Cancer, 9, 163-9.
22. Rabien A, Sanchez-Ruderisch H, Schulz P, et al (2011). The tumor suppressor p16 (INK4a) controls oncogenic K-Ras function in human pancreatic cancer cells. Cancer Sci, 10, 1349-56.
23. Radojicic J, Zaravinos A, Vrekoussis T, et al (2011). MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle, 10, 507-17.
24. Ramakers C, Ruijter JM, Deprez RH, et al (2003). Assumption reaction (PCR) data. Neurosci Lett, 339, 62-6.
25. Rask L, Balslev E, Jorgensen S, et al (2011). High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS, 119, 663-73.
26. Rhodes A, Jasani B, Anderson E, et al (2002). Evaluation of HER-2/neu Immunohistochemical Assay Sensitivity and Scoring on Formalin-Fixed and Paraffin-Processed Cell Lines and Breast Tumors :A Comparative Study Involving Results From Laboratories in 21 Countries. Am J Clin Pathol, 118, 408-17.
27. Ruijter JM, Ramakers C, Hoogaars WM, et al (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res, 37, 45.
28. Tang F, Hajkova P, Barton SC, et al (2006). Micro-RNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res, 34, 9.
29. Xu J, Wang B, Zhang Y, et al (2011). Clinical implications for BRCA gene mutation in breast cancer. Mol Biol Rep, 5, 2869.